semaglutide cardiovascular trial news risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 US study confirms cardiovascular benefits
Description
A physical therapist can tailor exercises to your specific needs, focusing on stretches and strength-building activities
In the STRIDE trial, once-weekly subcutaneous dosing of semaglutide significantly improved walking capacity and quality of life in patients with T2DM and symptomatic peripheral artery disease (PAD)
doi: 10.1007/s00125-016-4179-x
In 2023, 13.5 % of U.S
Its still a work in progress, but one I feel more in control of now
2024;17:e010936
